Stock ESPR ESPERION THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages Esperion Therapeutics, Inc.

Equities

ESPR

US29664W1053

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-31 pm EDT 		5-day change 1st Jan Change
2.16 USD -5.68% Intraday chart for Esperion Therapeutics, Inc. +1.41% -27.76%
May. 22 Daiichi Sankyo Europe GmbH and Esperion Therapeutics, Inc. Jointly Announce That European Commission Has Approved the Label Update of Both NILEMDO® (bempedoic acid) and NUSTENDI® (bempedoic acid / ezetimibe fixed-dose combination), as Treatments for Hypercholesterolemia and to Reduce the Risk of Adverse Cardiovascular Events CI
May. 20 Esperion Therapeutics Says Primary Endpoint Achieved in Hypercholesterolemia Treatment Phase 3 Trial; Shares Rise MT

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Esperion to Participate in Upcoming June Investor Conferences
First-In-Class Cholesterol-Lowering Treatment NILEMDO® (NEXLETOL® in the U.S.) and Its Combination with Ezetimibe, NUSTENDI® (NEXLIZET® in the U.S.), Approved In Europe To Treat Hypercholesterolemia and Significantly Reduce Cardiovascular Risk
First-In-Class Cholesterol-Lowering Treatment NILEMDO® (NEXLETOL® in the U.S.) and Its Combination with Ezetimibe, NUSTENDI® (NEXLIZET® in the U.S.), Approved In Europe To Treat Hypercholesterolemia and Significantly Reduce Cardiovascular Risk
Daiichi Sankyo Europe GmbH and Esperion Therapeutics, Inc. Jointly Announce That European Commission Has Approved the Label Update of Both NILEMDO® (bempedoic acid) and NUSTENDI® (bempedoic acid / ezetimibe fixed-dose combination), as Treatments for Hypercholesterolemia and to Reduce the Risk of Adverse Cardiovascular Events
Esperion - Bempedoic Acid Met Primary Endpoint of Phase 3 Trial in Japan for the Treatment for Hypercholesterolemia
Esperion Therapeutics Says Primary Endpoint Achieved in Hypercholesterolemia Treatment Phase 3 Trial; Shares Rise
Bempedoic Acid Met Primary Endpoint of Phase 3 Trial in Japan for the Treatment for Hypercholesterolemia
Transcript : Esperion Therapeutics, Inc. Presents at Bank of America Health Care Conference 2024, May-15-2024 03:00 PM
Esperion Receives Five Year Patent Extension for Bempedoic Acid, Contained in NEXLETOL® and NEXLIZET®
Esperion Receives Five Year Patent Extension for Bempedoic Acid, Contained in NEXLETOL® and NEXLIZET®
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(4)
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Investor Spotlight: Companies Poised for Growth Amid Recent Developments: VTAK, ESPR, FGEN, GSUN, INBS
Investor Sentiment Muted After Rate Cut Optimism, Stifling US Equity Futures Pre-Bell
Top Premarket Gainers
Transcript : Esperion Therapeutics, Inc., Q1 2024 Earnings Call, May 07, 2024
Esperion Therapeutics: Q1 Earnings Snapshot
Earnings Flash (ESPR) ESPERION THERAPEUTICS Posts Q1 Revenue $137.7M, vs. Street Est of $83.9M
Earnings Flash (ESPR) ESPERION THERAPEUTICS Posts Q1 EPS $0.34, vs. Street Est of $-0.01
Esperion Reports First Quarter 2024 Financial Results
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. ESPR Stock
  4. News Esperion Therapeutics, Inc.
  5. Other languages